tesamorelin and aod9604 vs sermorelin AOD-9604 Tesamorelin: Two Approaches to Growth Hormone-Related Research AOD-9604 AOD 9604 & FDA Approval:

Route: Injections are given intramuscularly (IM) , though subcutaneous (SC) is also possible in some cases

Bogatyrev, S

What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry

This service is not a substitute for evaluation and care by your primary care physician

Compounded Methionine, Inositol, Choline + B12 in a 10ml vial

Initial Injection vs At-Home Test The choice is clear